The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
D. Adkins
Honoraria - ImClone Systems; Lilly
Research Funding - Celgene
J. Ley
No relevant relationships to disclose
B. Nussenbaum
No relevant relationships to disclose
J. Diaz
No relevant relationships to disclose
R. Paniello
No relevant relationships to disclose
W. L. Thorstad
Honoraria - Bristol-Myers Squibb
H. A. Gay
No relevant relationships to disclose
J. Subramanian
No relevant relationships to disclose
T. M. Wildes
No relevant relationships to disclose
J. Mathai
No relevant relationships to disclose
T. Rachocki
No relevant relationships to disclose
D. I. Kuperman
No relevant relationships to disclose